Serina Therapeutics, Inc. (SER) shareholders
SERNYSEPharmaceutical PreparationsFiscal year ends December 31
$1.39−0.02 (-1.42%)
Close on Nov 13, 2026Market cap $35.31MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
5.5%
1M of 25M shares
Institutional holders
27
5 new, 3 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
7 buys · 22 sales
Net sold $281.55K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| JuvVentures (UK) Limited Joint filing with Juvenescence Limited (27.30%) | 4,400,781 | 27.30% | 13D (active) amendment | Mar 20, 2026 |
| Sio Capital Management, LLC | 2,000,000 | 7.87% | 13G (passive) amendment | Sep 30, 2026 |
| Randall Moreadith | 614,961 | 6.80% | 13D (active) | Mar 26, 2024 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of SER | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Sio Capital Management, LLC | 1,000,000 | 3.94% | $1.94M | – | 0.32% |
| Vanguard Capital Management LLC | 162,198 | 0.64% | $314.66K | +3,062 | 0.00% |
| Waverly Advisors, LLC | 67,492 | 0.27% | $130.93K | – | 0.00% |
| Geode Capital Management, LLC | 51,007 | 0.20% | $98.96K | −13,966 | 0.00% |
| Keel Point, LLC | 21,508 | 0.08% | $41.73K | – | 0.00% |
| Northern Trust Corp | 20,771 | 0.08% | $40.30K | New | 0.00% |
| Vanguard Fiduciary Trust Co | 20,009 | 0.08% | $38.82K | – | 0.00% |
| Avidian Wealth Solutions, LLC | 18,800 | 0.07% | $36.47K | – | 0.00% |
| Jane Street Group, LLC | 15,444 | 0.06% | $29.96K | −24,209 | 0.00% |
| State Street Corp | 12,758 | 0.05% | $24.75K | – | 0.00% |
| Caitong International Asset Management Co., Ltd | 3,744 | 0.01% | $7.26K | −238 | 0.00% |
| Wells Fargo & Company/Mn | 3,611 | 0.01% | $7.01K | +5 | 0.00% |
| Tower Research Capital LLC (TRC) | 2,570 | 0.01% | $4.99K | +1,727 | 0.00% |
| BlackRock, Inc. | 2,378 | 0.01% | $4.61K | −55,886 | 0.00% |
| Osaic Holdings, Inc. | 2,002 | 0.01% | $3.88K | +1,001 | 0.00% |
| UBS Group AG | 1,347 | 0.01% | $2.61K | +1,342 | 0.00% |
| Barclays PLC | 545 | 0.00% | $1.06K | New | 0.00% |
| Avion Wealth | 312 | 0.00% | $0 | New | 0.00% |
| Piscataqua Savings Bank | 28 | 0.00% | $54 | – | 0.00% |
| Morgan Stanley | 14 | 0.00% | $28 | +6 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 27 | 1M | 5.5% | 5 / 6 | 4 / 3 | 0M | 0M |
| Q1 2026 | 25 | 1M | 5.8% | 10 / 6 | 1 / 5 | 1M | 0M |
| Q4 2025 | 22 | 0M | 1.7% | 0 / 4 | 6 / 3 | 0M | 0M |
| Q3 2025 | 25 | 0M | 1.8% | 6 / 7 | 2 / 4 | 0M | 0M |
| Q2 2025 | 23 | 0M | 1.6% | 3 / 4 | 5 / 5 | 0M | 0M |
| Q1 2025 | 25 | 0M | 1.3% | 3 / 5 | 6 / 3 | 0M | 0M |
| Q4 2024 | 25 | 0M | 1.3% | 2 / 4 | 5 / 2 | 0M | 0M |
| Q3 2024 | 25 | 0M | 1.2% | 5 / 5 | 7 / 0 | 0M | 0M |
| Q2 2024 | 21 | 0M | 0.8% | 9 / 6 | 2 / 1 | 0M | 0M |
| Q1 2024 | 13 | 0M | 0.4% | 1 / 0 | 12 / 21 | 0M | 5M |
| Q4 2023 | 35 | 5M | 19.6% | 6 / 7 | 8 / 1 | 0M | 0M |
| Q3 2023 | 30 | 5M | 19.0% | 0 / 10 | 3 / 2 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
8 funds held SER in Q1 2026, 82% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of SER | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 125,805 | 0.50% | $244.06K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 45,248 | 0.18% | $83.26K | 0.00% | May 31, 2026 |
| Vanguard Extended Market Index Fund | 33,331 | 0.13% | $64.66K | 0.00% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 4,739 | 0.02% | $8.72K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 2,592 | 0.01% | $4.77K | 0.00% | May 31, 2026 |
| Ultra-Small Company Market Fund | 2,495 | 0.01% | $4.84K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Steven A. Ledger | Chief Executive Officer, Director | 238,027 | 0.94% | May 27, 2026 |
| Srini Tenjarla | SVP, CMC & Formulation | – | – | May 26, 2026 |
| Randall Moreadith | Chief Scientific Officer | 6,500 | 0.03% | May 26, 2026 |
| Gregory S. Curhan | Chief Financial Officer | – | – | May 26, 2026 |
| Farrell Simon | Director | – | – | Jul 23, 2026 |
| Stephen K. Brannan | Director | 1,000 | 0.00% | Jul 9, 2026 |
| Karen J. Wilson | Director | 30,100 | 0.12% | Jun 22, 2026 |
| Richard Peter Marshall | Director | 12,183 | 0.05% | Jun 22, 2026 |
| Jay Venkatesan | Director | 232,294 | 0.91% | Jun 22, 2026 |
| Gregory Bailey | Director | 1,897,445 | 7.47% | Jun 22, 2026 |
| Simba Gill | Director | – | – | Feb 17, 2026 |
| Ltd Juvenescence | 10% owner | 6,034,376 | 23.76% | Feb 3, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Stephen K. Brannan Director | Jul 7, 2026 | Buy | +1,000 | $2.03 | $2.03K | 1,000 |
| Jay Venkatesan Director | Jun 17, 2026 | Conversion | +224,152 | $2.25 | $504.34K | 231,705 |
| Gregory Bailey Director | Jun 17, 2026 | Conversion | +1,770,805 | $2.25 | $3.98M | 1,897,445 |
| Gregory Bailey Director | Jun 17, 2026 | Conversion | +6,666,667 | $2.25 | $15.00M | 8,564,382 |
| Karen J. Wilson Director | Jun 12, 2026 | Buy | +5,000 | $1.77 | $8.85K | 10,100 |
| Karen J. Wilson Director | Jun 11, 2026 | Buy | +5,100 | $1.75 | $8.93K | 5,100 |
| Steven A. Ledger Chief Executive Officer, Director | May 26, 2026 | Award | +10,100 | $1.93 | $19.49K | 10,100 |
| Jay Venkatesan Director | May 22, 2026 | Buy | +589 | $1.78 | $1.05K | 589 |
| Karen J. Wilson Director | May 22, 2026 | Buy | +10,000 | $1.93 | $19.30K | 20,000 |
| Karen J. Wilson Director | May 21, 2026 | Buy | +10,000 | $1.77 | $17.70K | 10,000 |
| Richard Peter Marshall Director | May 19, 2026 | Buy | +12,183 | $1.65 | $20.10K | 12,183 |
| Gregory Bailey Director | Mar 31, 2026 | Award | +59,667 | $1.94 | $115.75K | 126,910 |
| Jay Venkatesan Director | Mar 31, 2026 | Award | +7,553 | $1.94 | $14.65K | 7,553 |
| Randall Moreadith Chief Scientific Officer | Mar 23, 2026 | Option exercise | +6,500 | $0.06 | $390 | 6,500 |
| Randall Moreadith Chief Scientific Officer | Mar 23, 2026 | Sale(10b5-1 plan) | −6,500 | $2.86 | $18.59K | 0 |
| Randall Moreadith Chief Scientific Officer | Mar 19, 2026 | Sale(10b5-1 plan) | −39,000 | $2.50 | $97.50K | 0 |
| Randall Moreadith Chief Scientific Officer | Mar 19, 2026 | Option exercise | +39,000 | $0.06 | $2.34K | 39,000 |
| Randall Moreadith Chief Scientific Officer | Feb 2, 2026 | Sale(10b5-1 plan) | −6,500 | $3.03 | $19.70K | 0 |
| Randall Moreadith Chief Scientific Officer | Feb 2, 2026 | Option exercise | +6,500 | $0.06 | $390 | 6,500 |
| Randall Moreadith Chief Scientific Officer | Jan 28, 2026 | Sale(10b5-1 plan) | −6,500 | $3.57 | $23.21K | 0 |
| Randall Moreadith Chief Scientific Officer | Jan 28, 2026 | Option exercise | +6,500 | $0.06 | $390 | 6,500 |
| Randall Moreadith Chief Scientific Officer | Jan 22, 2026 | Sale(10b5-1 plan) | −2,500 | $2.95 | $7.38K | 0 |
| Randall Moreadith Chief Scientific Officer | Jan 22, 2026 | Option exercise | +2,500 | $0.06 | $150 | 2,500 |
| Randall Moreadith Chief Scientific Officer | Jan 21, 2026 | Option exercise | +2,000 | $0.06 | $120 | 2,000 |
| Randall Moreadith Chief Scientific Officer | Jan 21, 2026 | Sale(10b5-1 plan) | −2,000 | $3.00 | $6.00K | 0 |
| Randall Moreadith Chief Scientific Officer | Jan 20, 2026 | Sale(10b5-1 plan) | −2,000 | $3.07 | $6.14K | 0 |
| Randall Moreadith Chief Scientific Officer | Jan 20, 2026 | Option exercise | +2,000 | $0.06 | $120 | 2,000 |
| Randall Moreadith Chief Scientific Officer | Jan 14, 2026 | Sale(10b5-1 plan) | −1,084 | $2.50 | $2.71K | 0 |
| Randall Moreadith Chief Scientific Officer | Jan 14, 2026 | Option exercise | +1,084 | $0.06 | $65 | 1,084 |
| Randall Moreadith Chief Scientific Officer | Jan 13, 2026 | Option exercise | +5,416 | $0.06 | $325 | 5,416 |
| Randall Moreadith Chief Scientific Officer | Jan 13, 2026 | Sale(10b5-1 plan) | −5,416 | $2.50 | $13.54K | 0 |
| Randall Moreadith Chief Scientific Officer | Jan 8, 2026 | Option exercise | +13,000 | $0.06 | $780 | 13,000 |
| Randall Moreadith Chief Scientific Officer | Jan 8, 2026 | Sale(10b5-1 plan) | −13,000 | $2.69 | $34.97K | 0 |
| Randall Moreadith Chief Scientific Officer | Dec 23, 2025 | Option exercise | +4,100 | $0.06 | $246 | 4,100 |
| Randall Moreadith Chief Scientific Officer | Dec 23, 2025 | Sale(10b5-1 plan) | −4,100 | $2.60 | $10.66K | 0 |
| Randall Moreadith Chief Scientific Officer | Dec 22, 2025 | Option exercise | +5,673 | $0.06 | $340 | 5,673 |
| Randall Moreadith Chief Scientific Officer | Dec 22, 2025 | Sale(10b5-1 plan) | −5,673 | $2.67 | $15.15K | 0 |
| Randall Moreadith Chief Scientific Officer | Dec 16, 2025 | Option exercise | +3,227 | $0.06 | $194 | 3,227 |
| Randall Moreadith Chief Scientific Officer | Dec 16, 2025 | Sale(10b5-1 plan) | −3,227 | $2.96 | $9.55K | 0 |
| Randall Moreadith Chief Scientific Officer | Dec 12, 2025 | Option exercise | +1,700 | $0.06 | $102 | 1,700 |
| Randall Moreadith Chief Scientific Officer | Dec 12, 2025 | Sale(10b5-1 plan) | −1,700 | $3.26 | $5.54K | 0 |
| Randall Moreadith Chief Scientific Officer | Dec 11, 2025 | Option exercise | +3,555 | $0.06 | $213 | 3,555 |
| Randall Moreadith Chief Scientific Officer | Dec 11, 2025 | Sale(10b5-1 plan) | −3,555 | $3.24 | $11.52K | 0 |
| Randall Moreadith Chief Scientific Officer | Dec 10, 2025 | Sale(10b5-1 plan) | −645 | $3.35 | $2.16K | 0 |
| Randall Moreadith Chief Scientific Officer | Dec 10, 2025 | Award | +645 | $0.06 | $39 | 645 |
| Randall Moreadith Chief Scientific Officer | Dec 9, 2025 | Sale(10b5-1 plan) | −600 | $3.31 | $1.99K | 0 |
| Randall Moreadith Chief Scientific Officer | Dec 9, 2025 | Option exercise | +600 | $0.06 | $36 | 600 |
| Randall Moreadith Chief Scientific Officer | Dec 3, 2025 | Option exercise | +5,000 | $0.06 | $300 | 5,000 |
| Randall Moreadith Chief Scientific Officer | Dec 3, 2025 | Sale(10b5-1 plan) | −5,000 | $3.52 | $17.60K | 0 |
| Randall Moreadith Chief Scientific Officer | Dec 2, 2025 | Option exercise | +1,500 | $0.06 | $90 | 1,500 |
| Randall Moreadith Chief Scientific Officer | Dec 2, 2025 | Sale(10b5-1 plan) | −1,500 | $3.91 | $5.87K | 0 |
| Randall Moreadith Chief Scientific Officer | Nov 25, 2025 | Sale(10b5-1 plan) | −5,965 | $3.90 | $23.26K | 5,965 |
| Randall Moreadith Chief Scientific Officer | Nov 25, 2025 | Option exercise | +5,965 | $0.06 | $358 | 11,930 |
| Randall Moreadith Chief Scientific Officer | Nov 24, 2025 | Option exercise | +535 | $0.06 | $32 | 535 |
| Randall Moreadith Chief Scientific Officer | Nov 24, 2025 | Sale(10b5-1 plan) | −535 | $3.94 | $2.11K | 0 |
| Randall Moreadith Chief Scientific Officer | Nov 18, 2025 | Option exercise | +6,500 | $0.06 | $390 | 6,500 |
| Randall Moreadith Chief Scientific Officer | Nov 18, 2025 | Sale(10b5-1 plan) | −6,500 | $3.75 | $24.38K | 0 |
| Randall Moreadith Chief Scientific Officer | Nov 10, 2025 | Sale(10b5-1 plan) | −6,500 | $4.10 | $26.65K | 0 |
| Randall Moreadith Chief Scientific Officer | Nov 10, 2025 | Option exercise | +6,500 | $0.06 | $390 | 6,500 |
| Randall Moreadith Chief Scientific Officer | Nov 5, 2025 | Option exercise | +3,398 | $0.06 | $204 | 3,398 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Short % of float
0.37%
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
+6.6%
From 0M shares
Short volume, 20 days
32.7%
Of volume reported to FINRA
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Serina Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 829,377 shares on Sep 29, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Randall Moreadith Officer | Jan 20, 2026 | 91,000 | $279.37K | Jan 20, 2026 | Option Exercise |
| Randall Moreadith Officer | Oct 14, 2025 | 88,826 | $530.16K | Oct 13, 2025 | Option Exercise |
| Randall Moreadith Officer | Jun 30, 2025 | 99,674 | $576.06K | Jun 30, 2025 | Option Exercise |
See a number that looks wrong?